

Ad hoc announcement pursuant to Art. 53 LR
2026 half-year report – media release

Straumann Group delivers strong second-quarter performance and confirms upgraded profitability outlook for 2026

- Second-quarter revenue amounted to CHF 707.0 million, with organic growth accelerating to 8.5%; half-year revenue reached CHF 1.4 billion, representing 7.8% organic growth
- Core EBIT margin improved to 26.9% at constant 2025 exchange rates, or 25.7% including currency effects
- Continued market share gains in premium implantology, with iEXCEL driving customer conversions and new account wins, while Neodent continued its global expansion in the challenger segment
- Free cash flow increased by 49% to CHF 168.6 million, reflecting improved operating cash generation and lower capital expenditure following a period of significant capacity investments
- Upgraded profitability outlook for 2026 confirmed: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates

All figures refer to continuing operations in CHF million / margin rounded	H1 2026		H1 2025	
	IFRS	CORE ¹	IFRS	CORE ¹
Revenue	1 379.5	1 379.5	1 348.2	1 348.2
Change CHF		2.3%		5.9%
Change (CER ²)		7.8%		10.2%
Change organic		7.8%		10.2%
Gross profit	992.6	971.9	968.9	972.0
Margin	72.0%	70.5%	71.9%	72.1%
Margin change CHF		(160bps)		(40bps)
Margin change (CER ²)		(60bps)		10bps
EBITDA	435.3	431.5	418.2	428.5
Margin	31.6%	31.3%	31.0%	31.8%
Margin change CHF		(50bps)		(90bps)
Margin change (CER ²)		110bps		0bps
EBIT	350.6	354.8	329.6	358.1
Margin	25.4%	25.7%	24.4%	26.6%
Margin change CHF		(80bps)		(130bps)
Margin change (CER ²)		90bps		(40bps)
Net result	250.7	262.0	238	265.7
Margin	18.2%	19.0%	17.7%	19.7%
Margin change CHF		(70bps)		(250bps)
Basic EPS (in CHF)	1.57	1.64	1.49	1.66
Free cash flow	168.6		113.0	
Margin	12.2%		8.4%	
Headcount (end of June)	11 582		11 948	

¹ The “core” figures in this document exclude M&A effects from purchase-price allocation (PPA) amortization and related changes of contingent considerations, impairments, pension plan amendments, legal cases, restructuring expenses, consolidation result of former associates, and other non-recurring incidents. Details and a reconciliation of the reported and core income statement are provided on pages 9ff.

² Constant exchange rate (CER) equals prior-year figures at 2026 currency exchange rates

Basel, August 19, 2026: Straumann Group reported second-quarter revenue of CHF 707.0 million, with organic growth accelerating to 8.5% and 5.9% growth in Swiss francs year-on-year. First-half revenue reached CHF 1.4 billion, representing 7.8% organic growth or 2.3% growth in Swiss francs. This strong and accelerated performance demonstrates that the execution of our strategy, as presented at our last Capital Markets Day, is translating into tangible results. Growth was well-balanced across regions. Europe, Middle East and Africa and North America both delivered organic growth above 8%. Asia Pacific returned to growth despite the continued impact of China, while Latin America delivered another quarter of double-digit growth. Performance was driven by digital solutions, premium and challenger implantology, and orthodontics. Digital solutions are playing an increasingly important role, supported by strong intraoral scanner sales, particularly SIRIOS X3, and by the cloud-based Straumann AXS platform, whose open architecture helped expand the user base, strengthening the foundation of the Straumann Group ecosystem, critical for future connected-workflow growth. In premium implantology, iEXCEL continued to drive customer conversions and new account acquisition resulting in market share gains in all key geographies. Neodent further expanded its geographic reach, strengthening the Group's global position across the challenger segment. In parallel, continued operational leverage translated revenue growth into higher profitability at constant 2025 exchange rates. Manufacturing productivity, supply-chain optimization and disciplined resource management combined with the improving profitability profiles of the orthodontics and intraoral scanner business supported a core EBIT margin of 26.9% at constant 2025 exchange rates. Free cash flow increased to CHF 168.6 million.

Guillaume Daniellot, Chief Executive Officer, commented: "We delivered a strong second quarter and first half, with growth across all regions, especially from mature markets, and a significant improvement in profitability at constant exchange rates. Our performance demonstrates future growth potential in premium implantology through iEXCEL and differentiated treatment workflows, while expanding access through Neodent and our broader multi-brand portfolio.

Our product leadership is helping us expand and outperform in all key specialty dental care markets. Our digital ecosystem is scaling rapidly, supported by strong intraoral scanner sales and a sharp increase in Straumann AXS users, creating a much larger installed base for future growth through connected workflows, consumables and implants. By combining product leadership with a superior customer experience, and by connecting innovation, digitalization and education, we are making treatments more efficient for clinicians and more accessible for patients.

At the same time, manufacturing productivity, supply-chain optimization and disciplined resource allocation are improving the scalability of our business while allowing us to continue investing in innovation and strategic growth priorities. This performance is also a reflection of our high-performance player-learner culture and the commitment of our teams around the world. Their entrepreneurial mindset and relentless focus on customers allow us to execute with speed and consistency. I would like to thank our colleagues for their outstanding contribution and our customers for their continued trust. We remain confident in delivering our upgraded outlook for 2026."

REGIONAL PERFORMANCE IN THE SECOND QUARTER

EMEA – strong growth led by premium and challenger implantology

The Europe, Middle East and Africa (EMEA) region reported revenue of CHF 285.1 million in the second quarter, representing 8.6% organic growth. Germany delivered solid growth, while Poland and Hungary showed particularly strong momentum, supported by positive contributions from several other established European markets, including Spain and Benelux. Implantology remained the principal growth driver, with iEXCEL attracting new customers and supporting further market share gains across mature European markets. Neodent and Anthogyr complemented this performance by expanding their reach in the challenger segment, while ClearCorrect continued to expand its presence among general practitioners (GPs).

NAM – iEXCEL driven market share gains continued while commercial execution supported the growth further

North America generated revenue of CHF 177.5 million in the second quarter, corresponding to a strong 8.4% organic growth, despite cautious consumer sentiment and broadly stable patient flow. The region continued to outperform the underlying implant market. Premium implantology led the performance with iEXCEL supporting double-digit new customer acquisition. The dental service organizations (DSO) segment remained an important contributor, supported by strategic customer partnerships and increasing adoption of integrated digital workflows. Neodent also gained new customers, while digital solutions recorded double-digit growth.

APAC – while rest of the region delivered a strong growth, China saw a sequential improvement

Asia Pacific recorded revenue of CH 177.6 million in the second quarter, achieving 7.4% organic growth. Excluding China, the region grew 25.0%, led by Japan, India, Australia and Southeast Asia. Premium implantology and the expansion of Neodent contributed to the performance. In China, results improved sequentially as patient flow recovered gradually and distributor inventories stabilized, while we expect VBP 2.0 to potentially begin its process in the second half of this year with an operational execution planned for very early 2027. Digital solutions posted strong growth, led by SIRIOS X3 and increased adoption in Australia, Korea, India and Vietnam.

LATAM – double-digit growth across premium, challenger and digital solutions

Latin America delivered revenue of CHF 66.8 million in the second quarter, representing 11.8% organic growth. Brazil and the Hispanic markets, particularly Mexico, Argentina and Colombia, were the main contributors. Premium implantology achieved double-digit growth, while Neodent expanded rapidly across Hispanic countries and maintained its leading position in Brazil. Digital solutions also recorded strong double-digit growth. The ongoing expansion of the Curitiba manufacturing site will further strengthen manufacturing efficiency and supply capabilities.

REVENUE BY REGION

Figures refer to continuing operations, in CHF million	Q2 2026	Q2 2025	H1 2026	H1 2025
Europe, Middle East & Africa (EMEA)	285.1	270.4	573.4	550.3
Change CHF	5.4%	3.5%	4.2%	5.9%
Change (CER ³)	8.6%	8.2%	8.2%	9.1%
Change organic	8.6%	8.2%	8.2%	9.1%
% of Group total	40.3	40.5	41.6	40.8
North America (NAM)	177.5	170.7	352.4	355.9
Change CHF	4.0%	(5.9%)	(1.0%)	(0.9%)
Change (CER ³)	8.4%	2.7%	8.1%	2.2%
Change organic	8.4%	2.7%	8.1%	2.2%
% of Group total	25.1	25.6	25.5	26.4
Asia Pacific (APAC)	177.6	169.3	324.8	331.5
Change CHF	4.9%	9.5%	(2.0%)	16.2%
Change (CER ³)	7.4%	16.4%	4.2%	19.6%
Change organic	7.4%	16.4%	4.2%	19.6%
% of Group total	25.1	25.4	23.5	24.6
Latin America (LATAM)	66.8	57.1	128.9	110.5
Change CHF	17.0%	(1.0%)	16.7%	1.3%
Change (CER ³)	11.8%	16.2%	15.4%	17.5%
Change organic	11.8%	16.2%	15.4%	17.5%
% of Group total	9.4	8.6	9.3	8.2
Group	707.0	667.5	1 379.5	1 348.2
Change CHF	5.9%	1.9%	2.3%	5.9%
Change (CER ³)	8.5%	9.3%	7.8%	10.2%
Change organic	8.5%	9.3%	7.8%	10.2%

STRATEGIC PROGRESS

Capital Markets Day priorities translating into tangible results

The three priorities set out at our 2025 Capital Markets Day are already visible in the execution of our strategy and the Group's performance: expanding leadership in implantology, transforming the orthodontics franchise and disrupting chairside prosthetics through connected digital workflows. In a global oral care market exceeding CHF 20 billion, these priorities continue to create further room for growth. The Group's growth model combines product leadership with customer experience, bringing innovation, digitalization and education together to simplify treatment and improve clinical efficiency. The Straumann Fast Molar solution illustrates this approach by linking iXCEL, intraoral scanning and restorative components in an integrated workflow.

³ Constant exchange rate (CER) equals prior-year figures at 2025 currency exchange rates

Premium innovation and Neodent expand implantology leadership

Premium implantology remained a key source of new customers and market share gains. iEXCEL represented close to 40% of Straumann premium implant volumes globally in the first half and increasingly serves as the platform for differentiated treatment solutions. Its adoption in mature markets demonstrates that clinical differentiation, workflow simplicity and education remain effective drivers of customer choice. Advanced training, particularly in full-arch treatment, extends this proposition into complex indications. In parallel, Neodent is increasing commercial and education investment in selected markets, while additional capacity in Curitiba prepares the brand for its next phase of global development. Together, Straumann and Neodent address distinct customer needs and price points while preserving differentiated clinical and brand propositions.

Digital ecosystem scales rapidly and unlocks future growth

Straumann's open, cloud-based AXS platform is scaling rapidly, driven by strong intraoral scanner sales, particularly SIRIOS X3, leading to a sharp increase in the user base. In the first half, the Group's AI-enabled case assessment solution already processed more cases than in full-year 2025, reflecting strong customer adoption and further improvements in output quality. Fast Molar is another implantology example of how iEXCEL, scanning and the healing abutment come together in one connected workflow, simplifying treatment and improving clinical efficiency. As more workflows are connected directly to the platform, AXS is becoming an increasingly important growth engine across implantology, prosthetics and orthodontics, with meaningful potential in connected workflows, consumables and implants.

ClearCorrect transformation progresses well, with stronger GP value proposition and adoption

ClearCorrect's transformation is progressing fast, with a more scalable and profitable operating model taking shape. New digital features such as case assessment and outcome simulation, together with the scalloped trimline, are strengthening the GP value proposition and supporting usage growth. The transfer of production for EMEA and APAC to the Smartee platform has improved production quality, delivery predictability and cost efficiency, keeping ClearCorrect on course to reach break-even by the end of 2027.

China strategy provides local capabilities and multiple options

China remains a large and comparatively underpenetrated implant market. Straumann Group has established a locally anchored platform spanning manufacturing, education, digital solutions and partnerships. The Shanghai campus is localizing production and lowering local-for-local costs, while the locally developed Medentika China implant line broadens the offering and unlocks additional underpenetrated market opportunities. Together with the Group's premium and challenger brands, these capabilities provide flexibility to respond to different VBP 2.0 scenarios while strengthening competitiveness and the local cost position.

FINANCIAL PERFORMANCE

To facilitate a like-for-like comparison, the Group presents core results in addition to results reported under IFRS Accounting Standards. In the first six months of 2026, the following pre-tax effects were defined as non-core items:

- M&A-related amortization and changes in the fair value of related contingent considerations amounting to CHF 13.9 million
- Legal case costs amounting to CHF 18.0 million, related to the US patent and antitrust litigation with Align Technology. In June 2026, the jury found neither party liable; the verdict may be subject to appeal.
- A pension-plan effect of CHF 1.0 million
- Other non-recurring income of CHF 21.6 million, primarily related to tariff refunds

A reconciliation table and detailed information are provided on pages 9ff. of this media release.

Core gross profit margin remains at a high level

In the first six months of 2026, the Group generated core gross profit of CHF 971.9 million, representing a currency-adjusted increase of CHF 63.0 million compared with the prior-year period. The corresponding core gross margin was 70.5%. Underlying gross margin performance improved, supported by a better product mix, lower COGS and the ramp-up of local production in Shanghai. This was partly offset by a one-off charge related to the technology upgrade of CNC milling and by tariff-related effects. IFRS gross profit amounted to CHF 992.6 million, corresponding to a margin of 72.0%, including tariff-related refunds classified as non-core.

Core EBIT margin improved to 26.9% at constant 2025 exchange rates

IFRS EBIT reached CHF 350.6 million, corresponding to a margin of 25.4%, an increase of 100 basis points year-on-year. Core EBIT amounted to CHF 354.8 million, with a margin of 26.9% at constant 2025 exchange rates or 25.7% including currency effects.

Profitability benefited from operational leverage, manufacturing efficiencies, supply-chain optimization and disciplined resource management. Core operating expenses increased in absolute terms as the Group continued to invest in commercial capabilities, innovation, digital platforms and strategic priorities. However, core operating expenses as a percentage of revenue improved by approximately 130 basis points compared with the prior-year period at current-year exchange rates.

Core net profit increased to CHF 262 million, up 15.7%

Core net financial expenses amounted to CHF 25.6 million. Income taxes totaled CHF 60.7 million, corresponding to an income tax rate of 18.8%.

Core net profit reached CHF 262.0 million, resulting in a margin of 19.0%. Core basic earnings per share amounted to CHF 1.64, compared with CHF 1.66 in the prior-year period.

Free cash flow increased to CHF 169 million

Free cash flow increased by 49% to CHF 168.6 million, supported by higher operating cash flow and lower capital expenditure. After several years of significant capacity investments, the Group now has the manufacturing footprint in place to support growth in the coming years, which should allow for a lower capital expenditure intensity going forward. Capital expenditure amounted to CHF 74.1 million, compared with CHF 113.0 million in the prior-year period, as investments continued in the Shanghai campus, the expansion of the Curitiba site and other productivity and digitalization initiatives. Cash and cash equivalents amounted to CHF 381.0 million at 30 June 2026. The Group reported a net cash position of CHF 34.7 million and maintained a solid equity ratio of 58.6%, providing financial flexibility to support organic growth, innovation and strategic investments.

UPDATED OUTLOOK FOR THE FULL-YEAR 2026 – BARRING UNFORESEEN EVENTS

Straumann Group continues to expect high single-digit organic revenue growth for the full-year 2026 and confirms its profitability guidance, raised in June, for core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates. The improvement is expected to be evenly distributed between the first and second half of the year.

The Group remains confident in its ability to deliver on its outlook, supported by the significant growth opportunities in its global CHF 20 billion addressable market, its resilient business model with strong market positions in a continued volatile environment, its innovation and transformation initiatives, and its highly engaged, entrepreneurial culture driving disciplined execution. Its broad global footprint provides a solid foundation for capturing significant growth opportunities in the global oral care market.

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CAD/CAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

Headquartered in Basel, Switzerland, the Group currently employs around 12 000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: + 41 (0)61 965 11 11

Homepage: www.straumann-group.com

Contacts

Corporate Communications

Silvia Dobry: +41 (0)61 965 15 62

Marc Kaiser: +41 (0)61 965 16 80

E-mail: corporate.communication@straumann.com

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

Derya Güzel: +41 (0)61 965 18 76

E-mail: investor.relations@straumann.com

ANALYSTS' AND MEDIA CONFERENCE CALL

Straumann will present its half-year 2026 results to representatives of the financial community and media in a webcast conference call today at 10.30 a.m. CEST. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.

If you intend to ask a question during the Q&A session, we kindly ask you to pre-register for the conference call through this [link](#). We also recommend that you download the presentation file in advance using the direct link in this media release before joining the conference call.

Presentation

The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

UPCOMING CORPORATE / INVESTOR EVENTS

2026	Event	Location
20-21 August	Octavian Roadshow	Zurich & Geneva
1 September	Octavian HC Field Trip	Basel
2-3 September	Bernstein Radshow	Copenhagen & Stockholm
2 September	BNP Paribas Bus Tour	Basel
9 September	Goldman Sachs European MedTech Conference	London
22-23 September	Bank of America Global Healthcare Conference	London
25 September	Barclays EU MedTech & Life Sciences Investor Trip	Virtual
30 September-27 October	Quiet period	
28 October	Third-quarter 2026 results	Webcast

Disclaimer

This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

Interim selected financial information

OPERATING PERFORMANCE FROM CONTINUING OPERATIONS

(in CHF million; based on IFRS Accounting Standards)	H1, 2026	H1, 2025
Revenue	1 379.5	1 348.2
Change in %	2.3	5.9
Gross profit	992.6	968.9
Margin in %	72.0	71.9
Operating result before depreciation and amortization (EBITDA)	435.3	418.2
Margin in %	31.6	31.0
Margin change in bps	50.0	(90.0)
Operating result (EBIT)	350.6	329.6
Margin in %	25.4	24.4
Margin change in bps	100.0	(190.0)
Net profit	250.7	238.2
Margin in %	18.2	17.7
Margin change in bps	50.0	(340.0)
Basic earnings per share (in CHF)	1.57	1.49

FINANCIAL PERFORMANCE FROM CONTINUING OPERATIONS

(in CHF million; based on IFRS Accounting Standards)	H1, 2026	H1, 2025
Cash and cash equivalents	381.0	246.5
Net working capital (net of cash)	580.9	470.9
Net cash (net debt)	34.7	(8.2)
Inventories	498.1	458.1
Days of supplies	235	218
Trade receivables	594.0	511.0
Days of sales outstanding	76	69
Balance sheet total	3 898.1	3 511.8
Return on assets in % (ROA)	10.0	12.1
Equity	2 285.8	2 061.0
Equity ratio in %	58.6	58.7
Return on equity in % (ROE)	17.0	20.9
Capital employed	1 933.0	1 776.0
Return on capital employed in % (ROCE)	30.9	33.9
Cash flows from operating activities from continuing operations	241.2	225.4
in % of revenue	17.5	16.7
Investments from continuing operations	85.6	125.5
in % of revenue	6.2	9.3
thereof capital expenditures	74.1	113.0
thereof business combination related	0.0	2.5
thereof contingent consideration related	11.5	10.0
Free cash flow from continuing operations	168.6	113.0
in % of revenue	12.2	8.4
Dividend	158.6	151.3

Alternative Performance Measures

The financial information in this first half report includes certain alternative performance measures (APMs), which are not accounting measures defined by IFRS® Accounting Standards.

CORE FINANCIAL MEASURES are non-IFRS Accounting Standards measures because they cannot be derived directly from Group consolidated financial statements. Management believes that these measures, when presented alongside reported results, will offer readers valuable supplementary information to better understand the Group's financial performance and position on a comparable basis over time. These core financial measures are not a substitute for, or superior to, financial measures prepared in accordance with IFRS Accounting Standards. In the periods under review, core financial measures are adjusted to exclude the following significant items:

- **M&A:** Special items and amortization of intangible assets resulting from the purchase price allocation (PPA) following acquisitions and changes in the fair value of related contingent considerations.
- **Impairments:** Impairment write-offs of financial or non-financial assets as a result of unusual or one-time events in legal or economic conditions, change in consumer demands, or damage that impacts the asset. The charge recognized in the first half of 2025 relates to the planned relocation of the Group's headquarters and the resulting underutilization of the current leased premises (see Note 6).
- **Restructuring:** One-off costs resulting from major restructuring exercises. In the first half of 2026, no material restructuring expenses were incurred. In the first half of 2025, restructuring expenses were incurred across the APAC and EMEA sales regions, as well as within the Operations segment.
- **Legal cases:** Extraordinary litigations brought against the Group with expected significant charges per case, including legal fees and settlement amounts. Expenses related to legal disputes in the course of the Group's ordinary business activities are not adjusted. The amount disclosed in H1 2026 and 2025 relates to the US patent and antitrust litigation with Align Technology.
- **Pension plan:** One-time settlements, plan amendment gains or losses stemming from pension accounting. The amount recognized in the first half of 2026 relates to a plan curtailment gain.
- **Consolidation result of former associates:** Remeasurement gains and losses as a result of obtaining control over former associates.
- **Other:** Non-recurring, unusual and infrequent incidents that cannot be allocated to any of the preceding categories. In the first half of 2026, the Group recognized refunds related to US tariffs.

A reconciliation of IFRS Accounting Standards to core measures is disclosed in the table at the end of this section.

Further, the Group discloses **VARIOUS KEY PERFORMANCE INDICATORS (KPI)**. Unless otherwise stated, the following KPIs are based on IFRS Accounting Standards figures (continuing basis), as disclosed in the consolidated financial statements:

ORGANIC REVENUE GROWTH

Revenue growth excluding the revenue contribution from business combinations (calculated by adding pre-acquisition revenues of the prior period to the existing revenue growth base) and currency effects.

REVENUE GROWTH IN LOCAL CURRENCIES

Revenue growth excluding currency effects. Those effects are calculated using a simulation by reconsolidating the prior-period revenues with the current-year foreign exchange translation rates.

NET CASH (NET DEBT)

Net debt is an indicator of the Group's ability to meet financial commitments, to pay dividends and undertake acquisitions. The KPI is calculated by subtracting financial liabilities (excluding lease liabilities) from cash and cash equivalents.

NET WORKING CAPITAL (NET OF CASH)

Working capital is capital invested in the Group's operating activities. It is a driver of cash flow and an indicator of operational efficiency. Net working capital combines the subtotals of current assets and current liabilities, excluding the lines cash and cash equivalents, current financial assets and current financial liabilities.

DAYS OF SUPPLIES (DOS)

The days of supplies indicate the average time in days that the Group takes to turn its inventory. The numerator is the balance sheet position "inventories" at the balance sheet date, and the denominator is the "cost of goods sold" of the past three months, multiplied by 90 days.

DAYS OF SALES OUTSTANDING (DSO)

The days of sales outstanding indicate the average number of days the Group takes to collect its receivables. The numerator is the balance sheet position "trade receivables" at the balance sheet date and the denominator is the "net revenue" of the past three months, multiplied by 90 days.

RETURN ON ASSETS (ROA)

Return on assets expresses the earning power of the Group's assets. The numerator is the profit for the period of the past twelve months, and the denominator is the average balance sheet total for the same period.

EQUITY RATIO

The equity ratio is calculated by dividing total equity by total assets.

RETURN ON EQUITY (ROE)

Return on equity compares profitability of the Group in relation to the equity invested. The numerator is the profit for the period of the past twelve months and the denominator is the average equity for the same period.

CAPITAL EMPLOYED

Capital employed equals current assets, property, plant and equipment, right-of-use assets, intangible assets, minus cash and cash equivalents and non-interest-bearing liabilities.

RETURN ON CAPITAL EMPLOYED (ROCE)

Return on capital employed expresses the earning power of the Group's invested capital. The numerator is the operating profit (EBIT) of the past twelve months, and the denominator is the average capital employed for the same period.

FREE CASH FLOW

Free cash flow represents the cash-generating capability of the Group to conduct and maintain its operations, to finance dividend payments, to repay debt, and to undertake acquisitions. Free cash flow equals net cash from operating activities less purchase of property, plant and equipment, less purchase of intangible assets, plus net proceeds from property, plant and equipment.

CORE RESULTS RECONCILIATION H1, 2026

H1, 2026 (in CHF 1 000)	IFRS	M&A	Impairments	Legal cases	Pension plan settlements	Other	CORE
Revenue	1 379 469						1 379 469
Cost of goods sold	(386 854)	60				(20 816)	(407 611)
Gross profit	992 615	60				(20 816)	971 858
Other income	8 194						8 194
Distribution expense	(268 111)	2 949					(265 162)
Administrative expense	(382 138)	5 050		18 000	(991)		(360 079)
Operating profit	350 560	8 059		18 000	(991)	(20 816)	354 811
Finance income	43 032	(4 977)				(741)	37 315
Finance expense	(73 787)	10 845					(62 942)
Share of result of associates	(6 483)						(6 483)
Profit before income tax	313 321	13 928		18 000	(991)	(21 557)	322 701
Income tax expense	(62 641)	(1 453)		(2 493)	137	5 734	(60 716)
NET PROFIT FROM CONTINUING OPERATIONS	250 680	12 475		15 507	(854)	(15 823)	261 985
Loss from discontinued operations, net of tax	0						0
NET PROFIT	250 680	12 475		15 507	(854)	(15 823)	261 985
Attributable to:							
Shareholders of the parent company	249 703	12 434		15 507	(854)	(15 823)	260 967
Non-controlling interests	977	41					1 018
Basic earnings per share (in CHF)	1.57						1.64
Diluted earnings per share (in CHF)	1.57						1.64
Basic earnings per share continuing operations (in CHF)	1.57						1.64
Diluted earnings per share continuing operations (in CHF)	1.57						1.64
Operating profit	350 560	8 059		18 000	(991)	(20 816)	354 811
Depreciation, amortization and impairment	84 779	(8 059)					76 720
EBITDA	435 339			18 000	(991)	(20 816)	431 531

CORE RESULTS RECONCILIATION H1, 2025

H1, 2025 (in CHF 1 000)	IFRS	M&A	Impairments	Legal cases	Restructuring	Consolidation result former associates	CORE
Revenue	1 348 199						1 348 199
Cost of goods sold	(379 340)	62			3 124		(376 154)
Gross profit	968 860	62			3 124		972 046
Other income	4 382				419		4 801
Distribution expense	(247 397)	3 099			2 255		(242 043)
Administrative expense	(396 231)	5 550	9 506	3 000	1 455		(376 721)
Operating profit	329 613	8 710	9 506	3 000	7 254		358 082
Finance income	84 207	(7 421)				(687)	76 098
Finance expense	(112 451)	11 955				482	(100 014)
Share of result of associates	(8 866)						(8 866)
Profit before income tax	292 502	13 244	9 506	3 000	7 254	(206)	325 300
Income tax expense	(54 317)	(2 089)	(1 317)	(331)	(1 534)		(59 589)
NET PROFIT FROM CONTINUING OPERATIONS	238 185	11 155	8 189	2 669	5 719	(206)	265 711
Loss from discontinued operations, net of tax	(790)						(790)
NET PROFIT	237 395	11 155	8 189	2 669	5 719	(206)	264 921
Attributable to:							
Shareholders of the parent company	236 443	11 111	8 189	2 669	5 719	(206)	263 925
Non-controlling interests	952	44					996
Basic earnings per share (in CHF)	1.48						1.66
Diluted earnings per share (in CHF)	1.48						1.65
Basic earnings per share continuing operations (in CHF)	1.49						1.66
Diluted earnings per share continuing operations (in CHF)	1.49						1.66
Operating profit	329 613	8 710	9 506	3 000	7 254		358 082
Depreciation, amortization and impairment	88 634	(8 710)	(9 506)		(16)		70 402
EBITDA	418 247			3 000	7 237		428 485

Interim condensed consolidated statement of financial position

ASSETS

(in CHF 1 000)	30 Jun 2026	31 Dec 2025
Property, plant and equipment	609 389	578 251
Right-of-use assets	147 966	152 023
Intangible assets	878 937	872 229
Investments in associates	254 503	259 925
Financial assets	120 860	90 069
Other receivables	30 790	30 867
Deferred income tax assets	137 387	128 526
Total non-current assets	2 179 832	2 111 890
Inventories	498 107	476 139
Trade and other receivables	771 391	635 644
Financial assets	33 615	36 502
Income tax receivables	34 190	22 561
Cash and cash equivalents	380 988	475 426
Total current assets	1 718 291	1 646 272
TOTAL ASSETS	3 898 123	3 758 162

EQUITY AND LIABILITIES

(in CHF 1 000)	30 Jun 2026	31 Dec 2025
Share capital	1 595	1 595
Retained earnings and reserves	2 279 328	2 158 915
Total equity attributable to the shareholders of the parent company	2 280 923	2 160 510
Non-controlling interests	4 846	4 237
Total equity	2 285 769	2 164 747
Other liabilities	234 655	229 046
Income tax liabilities	17 439	17 438
Financial liabilities	474 622	473 741
Provisions	33 096	23 178
Retirement benefit obligations	29 724	43 599
Deferred income tax liabilities	63 692	62 803
Total non-current liabilities	853 228	849 805
Trade and other payables	584 826	587 685
Financial liabilities	36 314	35 310
Income tax liabilities	105 444	82 889
Provisions	32 542	37 725
Total current liabilities	759 126	743 609
Total liabilities	1 612 354	1 593 414
TOTAL EQUITY AND LIABILITIES	3 898 123	3 758 162

Interim condensed consolidated income statement

(in CHF 1 000)	H1, 2026	H1, 2025
Revenue	1 379 469	1 348 199
Cost of goods sold	(386 854)	(379 340)
Gross profit	992 615	968 860
Other income	8 194	4 382
Distribution expense	(268 111)	(247 397)
Administrative expense	(382 138)	(396 231)
Operating profit	350 560	329 613
Finance income	43 032	84 207
Finance expense	(73 787)	(112 451)
Share of result of associates	(6 483)	(8 866)
Profit before income tax	313 321	292 502
Income tax	(62 641)	(54 317)
NET PROFIT FROM CONTINUING OPERATIONS	250 680	238 185
Loss from discontinued operations, net of tax	0	(790)
NET PROFIT	250 680	237 395
Attributable to:		
Shareholders of the parent company	249 703	236 443
Non-controlling interests	977	952
Earnings per share (EPS) attributable to ordinary shareholders of the parent company:		
Basic EPS (in CHF)	1.57	1.48
Diluted EPS (in CHF)	1.57	1.48
Basic EPS continuing operations (in CHF)	1.57	1.49
Diluted EPS continuing operations (in CHF)	1.57	1.49

Interim condensed consolidated statement of comprehensive income

(in CHF 1 000)	H1, 2026	H1, 2025
Net profit	250 680	237 395
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:		
Net foreign exchange result on net investment loans	11 735	(25 630)
Share of other comprehensive income/(loss) of associates accounted for using the equity method	(224)	21
Exchange differences on translation of foreign operations	54 140	(65 449)
Income tax effect	(1 507)	3 699
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	64 144	(87 358)
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent periods:		
Change in fair value of financial instruments designated through other comprehensive income	252	(366)
Remeasurements of retirement benefit obligations	14 449	23 590
Income tax effect	(2 035)	(3 306)
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent periods	12 666	19 918
Other comprehensive income/(loss), net of tax	76 810	(67 440)
TOTAL COMPREHENSIVE INCOME, NET OF TAX	327 490	169 955
Attributable to:		
Shareholders of the parent company	326 524	169 121
Non-controlling interests	966	834

Interim condensed consolidated cash flow statement

(in CHF 1 000)	H1, 2026	H1, 2025
Net profit from continuing operations	250 680	238 185
Adjustments for:		
Income tax	62 641	54 317
Net interest result	7 901	8 519
Share of result of associates	6 483	8 866
Share-based payments expense	12 710	11 080
Net foreign exchange differences	6 096	17 821
Other non-cash items	(764)	(842)
Depreciation and amortization	81 726	79 077
Impairment	3 053	9 557
Change in provisions, retirement benefit obligations and other liabilities	9 789	(5 081)
Change in long-term assets	1 192	(1 056)
Working capital adjustments:		
Change in inventories	(11 505)	(46 391)
Change in trade and other receivables	(115 151)	(54 869)
Change in trade and other payables	(3 513)	(26 236)
Interest paid on lease liabilities	(3 671)	(4 176)
Interest paid	(3 643)	(2 921)
Interest received	2 555	3 216
Income tax paid	(65 412)	(63 643)
Cash flows from operating activities from continuing operations	241 168	225 423
Cash flows from operating activities from discontinued operations	(2 497)	(6 006)
Cash flows from operating activities	238 671	219 417

Interim condensed consolidated cash flow statement

(in CHF 1 000)	H1, 2026	H1, 2025
Purchase of financial assets	(26 271)	(25 649)
Proceeds from sale of financial assets	4 255	5 564
Purchase of property, plant and equipment	(57 359)	(91 240)
Purchase of intangible assets	(16 696)	(21 713)
Acquisition of a business, net of cash acquired	0	(2 546)
Disposal of a business, net of cash disposed	0	(860)
Contingent consideration paid	(11 533)	(10 000)
Proceeds from loans	3	234
Disbursement of loans	(242)	(11 929)
Dividends received from associates	1 179	1 055
Net proceeds from sale of non-current assets	1 451	565
Cash flows from investing activities from continuing operations	(105 212)	(156 518)
Cash flows from investing activities from discontinued operations	0	0
Cash flows from investing activities	(105 212)	(156 518)
Repayment of non-current financial debts	0	(30)
Increase in non-current financial debts	2 052	2 862
Increase / (repayment) of current financial debts	12	2 482
Dividends paid to the equity holders of the parent	(158 602)	(151 340)
Dividends paid to non-controlling interests	(391)	(513)
Payment of lease liabilities	(14 814)	(14 026)
Sale of treasury shares	10 488	11 888
Purchase of treasury shares	(69 328)	(23 016)
Cash flows from financing activities from continuing operations	(230 583)	(171 693)
Cash flows from financing activities from discontinued operations	0	0
Cash flows from financing activities	(230 583)	(171 693)
Exchange rate differences on cash held	2 685	(20 172)
Net change in cash and cash equivalents	(94 438)	(128 966)
Cash and cash equivalents at 1 January	475 426	375 492
CASH AND CASH EQUIVALENTS AT 30 JUNE	380 988	246 526

Interim condensed consolidated statement of changes in equity

H1, 2026

(in CHF 1 000)	Attributable to the shareholders of the parent company						Non-controlling interests	Total equity
	Share capital	Share premium	Treasury shares	Translation reserves	Retained earnings	Total		
At 1 January 2026	1 595	892	(448)	(717 492)	2 875 964	2 160 510	4 237	2 164 747
Net profit					249 703	249 703	977	250 680
Other comprehensive income / (loss)				64 379	12 442	76 821	(10)	76 810
Total comprehensive income / (loss)	0	0	0	64 379	262 145	326 524	966	327 490
Dividends to equity holders of the parent					(158 602)	(158 602)		(158 602)
Dividends to non-controlling interests						0	(484)	(484)
Share-based payment transactions					11 449	11 449		11 449
Purchase of treasury shares			(69 328)			(69 328)		(69 328)
Usage of treasury shares			16 605		(6 116)	10 488		10 488
Put options to non-controlling interests					(119)	(119)	127	8
AT 30 JUNE 2026	1 595	892	(53 171)	(653 113)	2 984 721	2 280 923	4 846	2 285 769

H1, 2025

(in CHF 1 000)	Attributable to the shareholders of the parent company						Non-controlling interests	Total equity
	Share capital	Share premium	Treasury shares	Translation reserves	Retained earnings	Total		
At 1 January 2025	1 595	61 428	(526)	(610 661)	2 588 296	2 040 131	3 661	2 043 792
Net profit					236 443	236 443	952	237 395
Other comprehensive income/(loss)				(87 261)	19 939	(67 322)	(118)	(67 440)
Total comprehensive income/(loss)	0	0	0	(87 261)	256 382	169 121	834	169 955
Dividends to equity holders of the parent		(60 536)			(90 804)	(151 340)		(151 340)
Dividends to non-controlling interests						0	(513)	(513)
Share-based payment transactions					9 995	9 995		9 995
Purchase of treasury shares			(23 016)			(23 016)		(23 016)
Usage of treasury shares			23 526		(11 638)	11 888		11 888
Put options to non-controlling interests					(111)	(111)	364	253
AT 30 JUNE 2025	1 595	892	(16)	(697 922)	2 752 120	2 056 667	4 346	2 061 014

Notes to the interim condensed consolidated financial statements

1 CORPORATE INFORMATION

Straumann Holding AG is a public company incorporated and domiciled in Switzerland, whose shares are publicly traded on the SIX Swiss Exchange. The unaudited interim condensed consolidated financial statements of the Straumann Group for the six months ending 30 June 2026 were authorized for issue in accordance with a resolution of the Board of Directors on 18 August 2026.

2 BASIS OF PREPARATION AND ACCOUNTING POLICIES

BASIS OF PREPARATION

The interim condensed consolidated financial statements for the six months ending 30 June 2026 have been prepared in accordance with IAS 34 'Interim Financial Reporting'. They provide an update of previously reported information and should be read in conjunction with the Group's annual financial statements as at 31 December 2025. All values disclosed are rounded to the nearest thousand except where otherwise indicated.

The preparation of consolidated financial statements under IFRS requires Management to make estimates and assumptions that affect the reported amounts. Because of the inherent uncertainties, actual outcomes and results may differ from these estimates and assumptions.

CHANGES TO THE GROUP'S ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2025, except for the adoption of new standards and amendments to existing standards effective as of 1 January 2026. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments apply for the first time in 2026, but do not have a material impact on the interim condensed consolidated financial statements of the Group.

3 DISAGGREGATED REVENUE FROM CONTRACTS WITH CUSTOMERS

The Group derives revenue from contracts with customers in the geographical regions, disclosed in Note 4.

4 SEGMENT INFORMATION

Operating segments for reporting purposes are determined based on the Group's management approach. The external segment reporting aligns with the internal organizational and management structure used within the Group and the financial reporting to the Chief Operating Decision Maker (CODM), identified as the Executive Management Board (EMB). The EMB is responsible for the Group's operational management, following the guidance of the Board of Directors. Additionally, it oversees global strategy and stakeholder management.

The reporting segments are presented consistently with the internal reporting to the CODM. The centralized headquarters support functions (e.g., finance, data+tech, human resources) and business units are not considered operating segments, as they do not generate separate revenues. Instead, these functions are grouped under the column "Not allocated items".

The Group's operating segment structure remains unchanged from that disclosed in the consolidated financial statements as of 31 December 2025. The comparative segment information for the six-month period ended 30 June 2025 has been restated to reflect the revised allocation of certain production facilities to the Operations segment.

SALES EUROPE, MIDDLE EAST AND AFRICA (EMEA)

Sales EMEA comprises the Group's own distribution businesses in the EMEA region, as well as business with EMEA distributors. The segment also includes the implant supported prosthetics business of Createch in Spain.

SALES NORTH AMERICA (NAM)

Sales NAM comprises the Group's own distribution businesses in the United States and Canada. It also includes the development and production activities of ClearCorrect in the US and US-based Bay Materials, a company specializing in the design, development and supply of high-performance thermoplastics for orthodontic applications. The segment also includes the development and production activities of Dental Wings in Canada.

SALES ASIA PACIFIC (APAC)

Sales APAC comprises the Group's own distribution businesses in the Asia Pacific region, as well as business with Asian distributors. It includes AlliedStar, a manufacturer of intraoral scanners (IOS) in China, the business of T-Plus, a Taiwanese company that develops and manufactures dental implant systems and has distribution channels in Taiwan and China, and Nihon, a Japanese provider of implant treatment referrals.

SALES LATIN AMERICA (LATAM)

Sales LATAM comprises the Group's own distribution businesses in Middle and South America as well as business with Latin American distributors. It includes the production sites of Neodent in Brazil (which manufactures implants, biomaterials, CAD/CAM products and clear aligners) and Yllor Biomaterials, a Brazilian company specializing in the development and manufacture of high-tech materials for 3D printing.

OPERATIONS

Operations acts as the principal for the Group's distribution businesses and comprises the Group's centralized manufacturing, logistics, and supply chain activities. The segment includes production facilities for implant components, instruments, and prosthetics, CAD/CAM milling centers, and facilities producing biomaterials and sterile-packaged products.

INFORMATION ABOUT PROFIT OR LOSS AND ASSETS

The following tables present revenue and profit information regarding the Group's operating segments for the six months ended 30 June 2026 and 30 June 2025, respectively.

H1, 2026
(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Revenue third party	567 098	356 992	327 081	128 298	0	0	0	1 379 469
Revenue inter-segment	25 261	19 267	20 940	46 612	749 313	0	(861 393)	0
Total revenue	592 359	376 259	348 021	174 910	749 313	0	(861 393)	1 379 469
Operating profit	12 192	59 570	60 993	22 767	460 836	(214 979)	(50 819)	350 560
Financial result								(30 756)
Share of result of associates								(6 483)
Profit before income tax								313 321
Income tax expense								(62 641)
NET PROFIT FROM CONTINUING OPERATIONS								250 680
Loss from discontinued operations, net of tax								0
NET PROFIT								250 680

H1, 2025 ¹
(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Revenue third party	543 259	363 968	330 882	110 090	0	0	0	1 348 199
Revenue inter-segment	17 854	25 869	17 119	36 587	783 281	0	(880 710)	0
Total revenue	561 113	389 837	348 001	146 677	783 281	0	(880 710)	1 348 199
Operating profit	32 029	(361)	35 780	27 167	514 771	(195 918)	(83 855)	329 613
Financial result								(28 245)
Share of result of associates								(8 866)
Profit before income tax								292 502
Income tax expense								(54 317)
NET PROFIT FROM CONTINUING OPERATIONS								238 185
Loss from discontinued operations, net of tax								(790)
NET PROFIT								237 395

¹ Comparative figures have been restated to reflect the revised allocation of certain production facilities to the Operations segment.

The following tables present the segment assets of the Group's operating segments as of 30 June 2026 and 31 December 2025:

at 30 Jun 2026
(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Segment assets	644 608	409 466	556 594	680 455	1 101 011	287 995	(709 358)	2 970 771
Unallocated assets								927 352
Group								3 898 123

at 31 Dec 2025
(in CHF 1 000)

	Sales EMEA	Sales NAM	Sales APAC	Sales LATAM	Operations	Not Allocated Items	Eliminations	Group
Segment assets	568 631	406 639	488 652	574 891	1 105 327	260 430	(636 855)	2 767 715
Unallocated assets								990 447
Group								3 758 162

SEASONALITY OF OPERATIONS

The Group operates in industries where significant seasonal or cyclical variations in total sales do not occur during the financial year.

5 BUSINESS COMBINATION

TRANSACTION IN 2026

No business combinations occurred during the six-month period ended 30 June 2026.

TRANSACTION IN 2025

maxon dental

On 10 June 2025, the Group increased its stake in maxon dental GmbH from 49.0% to full ownership. The company specializes in ceramic injection molding for dental implant components.

In H2 2025, the purchase price allocation (PPA) was completed. The PPA had no material effect on the Group's financial statements compared to the values which were provisionally recognized in H1 2025.

The fair values of the identifiable assets and liabilities as of the date of the business combination are as follows:

(in CHF 1 000)	Fair value
Property, plant and equipment	1 164
Technology	2 285
Deferred tax assets	446
Inventories	431
Trade and other receivables	516
Cash and cash equivalents	1 001
Total assets	5 843
Financial liabilities	2 199
Deferred income tax liabilities	573
Trade and other payables	254
Total liabilities	3 025
TOTAL IDENTIFIABLE NET ASSETS AT FAIR VALUE	2 818
Goodwill	4 139
Consideration	6 956
Satisfied in cash	3 548
Fair value of previously held interest	3 409
Consideration	6 956
Cash flow	
Net cash acquired	1 001
Cash paid	(3 548)
NET CASH OUTFLOW	(2 546)

At the date of the business combination, the fair value of trade receivables amounted to CHF 0.1 million and did not materially differ from the contractual gross amounts.

Goodwill, which is not deductible for tax purposes, reflects intangible assets that are not separately identifiable, such as expected synergy effects and employee know-how.

The Group's revenues and net profit for the first six months of 2025 were not materially impacted by the business combination.

6 IMPAIRMENT AND GOVERNMENT GRANT RELATED TO HEADQUARTERS RELOCATION

IMPAIRMENT OF RIGHT-OF-USE ASSETS

As part of the phased relocation of the Group's headquarters, the Group recognized an impairment loss of CHF 9.5 million in H1 2025. The loss relates to leased premises that are expected to become vacant in the future and will no longer be used for operational purposes. The impairment reflects the net present value of unavoidable lease payments for these non-utilized spaces. No impairment loss of right-of-use assets was recognized in H1 2026.

GOVERNMENT GRANT

As part of the strategic relocation of its corporate headquarters from Basel to Arlesheim, the Group established a cooperation framework with public authorities in the canton of Basel-Landschaft and the municipality of Arlesheim to support regional development. Under this framework, a grant receivable and a corresponding liability of CHF 5.0 million were recognized as of 30 June 2025, reflecting committed support for future relocation-related expenses. This amount has had no impact on the current and comparative period's income statement. The cooperation framework also includes discussions on potential support for further initiatives. As of the reporting date, key terms and amounts remain uncertain.

7 DISCONTINUED OPERATIONS

On 20 June 2024, the Group initiated formal proceedings to sell the direct-to-consumer aligner business (DTC business) with Zandivio plc (Impress Group). Founded in 2019, Impress Group is a leading provider of clear aligners in Europe and operates a network of clinics with a focus on Spain, the UK, Italy and Portugal.

The DTC business was sold on 5 September 2024 and is reported as a discontinued operation. The total net assets transferred to Impress Group amounted to CHF 79.3 million. In return, the Group received a 20% non-controlling stake in Impress Group with a fair value of CHF 82.5 million. The Group will maintain involvement in Impress Group, particularly as a supplier of aligners.

The expenses recognized in H1 2025 relate to indemnification settlements related to the disposal of the DTC business. In 2026, no income or expense from discontinued operations was recognized. Cash outflows from operating activities relating to discontinued operations amounted to CHF 2.5 million (H1 2025: CHF 6.0 million).

8 EARNINGS PER SHARE

BASIC EARNINGS PER SHARE

Basic earnings per share are calculated by dividing the net profit for the period attributable to ordinary shareholders of Straumann Holding AG by the weighted average number of ordinary shares outstanding during the year, excluding ordinary shares purchased by the Group and held as treasury shares.

	H1, 2026	H1, 2025
Net profit attributable to shareholders (in CHF 1 000)	249 703	236 443
Net profit attributable to shareholders - continuing operations (in CHF 1 000)	249 703	237 233
Weighted average number of ordinary shares outstanding	159 010 218	159 390 150
BASIC EARNINGS PER SHARE (IN CHF)	1.57	1.48
BASIC EARNINGS PER SHARE - CONTINUING OPERATIONS (IN CHF)	1.57	1.49

DILUTED EARNINGS PER SHARE

Diluted earnings per share are calculated by dividing the net profit for the period attributable to ordinary shareholders of Straumann Holding AG by the weighted average number of ordinary shares outstanding during the year, plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential of outstanding equity instruments into ordinary shares. The number of shares calculated as above is compared with the number of shares that would have been issued assuming the exercise of the Performance Share Units.

	H1, 2026	H1, 2025
Net profit attributable to shareholders (in CHF 1 000)	249 703	236 443
Net profit attributable to shareholders - continuing operations (in CHF 1 000)	249 703	237 233
Weighted average number of ordinary shares outstanding	159 010 218	159 390 150
Adjustments for instruments issued	527 455	252 932
Weighted average number of ordinary shares for diluted earnings per share	159 537 673	159 643 082
DILUTED EARNINGS PER SHARE (IN CHF)	1.57	1.48
DILUTED EARNINGS PER SHARE - CONTINUING OPERATIONS (IN CHF)	1.57	1.49

9 PROPERTY, PLANT AND EQUIPMENT & INTANGIBLE ASSETS

During the six months ended 30 June 2026, the Group acquired property, plant, and equipment at a cost of CHF 57.4 million (H1 2025: CHF 91.2 million) and invested in intangible assets amounting to CHF 16.7 million (H1 2025: CHF 21.7 million), excluding assets acquired through business combinations.

10 EQUITY

DIVIDENDS PAID

On 23 April 2026, Straumann Holding AG paid a dividend of CHF 1.00 per share (2025: CHF 0.95) to its shareholders. The total gross dividend paid amounted to CHF 158.6 million (2025: CHF 151.3 million).

11 FINANCIAL INSTRUMENTS

FAIR VALUES

The carrying amount of cash and cash equivalents, trade and other receivables and trade and other payables with a remaining term of up to twelve months, as well as other current financial assets and liabilities, represents a reasonable approximation of their fair values due to the short-term maturities of these instruments.

The fair value of equity instruments quoted in an active market is based on price quotations at the period-end date. For the domestic bond listed on the SIX Swiss Exchange, the fair value is derived from quoted market prices.

The fair value of the put options granted to non-controlling interests relates to the business combination of Abutment Direct Inc in 2019.

The fair value of derivatives is determined on the basis of input factors observed directly or indirectly on the market. The fair value of foreign exchange forward contracts and non-deliverable forwards is based on forward exchange rates. In 2024, the Group entered into financial derivatives to manage risks related to a component of the deferred consideration for the AlliedStar business combination. The fair value of these derivatives is influenced by the share price performance of Straumann Holding AG.

The unquoted equity instruments allocated to the Level 3 hierarchy mainly relate to investments in:

- a China-based medical device supplier,
- an Irish-based development and manufacturing company in the biomaterials sector,
- a non-listed US consumer health company in the dental sector, and
- a fund dedicated exclusively to investments in dental-related opportunities in China.

As the market for these investments is not active or no market is available, fair value is determined based on the best information available to the Group, such as the net asset value reports of the instruments.

The convertible bond classified within the Level 3 hierarchy is valued using a model that incorporates both observable and unobservable inputs. The loan component is valued by discounting future cash flows, while the option component is measured using a probability-weighted approach that reflects potential gains from an economically favorable conversion into equity shares. The valuation involves significant judgment in assessing key unobservable inputs, which could materially impact the fair value measurement.

Other financial liabilities allocated to the Level 3 hierarchy mainly include the contingent considerations in relation to the business combinations of AlliedStar in China, GalvoSurge in Switzerland and the Baltic and Polish distributors. The fair value of the contingent consideration is based on several components, such as profitability targets (for AlliedStar, Baltic and Polish distributors and GalvoSurge), company- and product related milestone achievements (for AlliedStar and GalvoSurge), and the share price of Straumann Holding AG shares (for AlliedStar).

The fair value of Level 3 investments and liabilities is reviewed regularly to assess whether there is any indication of a diminution in value.

Fair value hierarchy

The Group applies the following fair value hierarchy to classify financial instruments by valuation technique:

- Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities
- Level 2: Valuation techniques for which all significant inputs are observable, either directly or indirectly
- Level 3: Valuation techniques that use significant unobservable inputs

As of 30 June 2026 and 31 December 2025, the Group held the following financial instruments:

(in CHF 1 000)	30 Jun 2026					
	Carrying amount (by measurement basis)				Fair value	
	Amortized cost	Level 1	Level 2	Level 3		Total carrying amount
Financial assets						
Derivative financial assets			21 848		21 848	
Equity instruments				55 221	55 221	
Convertible bond				39 826	39 826	
Loans and other financial receivables	37 580				37 580	
Trade and other receivables	614 286				614 286	
Cash and cash equivalents	380 988				380 988	
Financial liabilities						
Straight bond	249 798				249 798	249 670
Derivative financial liabilities			2 579		2 579	
Put options to non-controlling interests				6 004	6 004	
Lease liabilities	164 652				164 652	
Other financial liabilities	87 903				87 903	
Trade and other liabilities	434 694			228 820	663 514	

(in CHF 1 000)

31 Dec 2025						
	Carrying amount (by measurement basis)				Fair value	
	Amortized cost	Level 1	Level 2	Level 3		Total carrying amount
Financial assets						
Derivative financial assets			24 637		24 637	
Equity instruments				31 731	31 731	
Convertible bond				34 600	34 600	
Loans and other financial receivables	35 603				35 603	
Trade and other receivables	510 416				510 416	
Cash and cash equivalents	475 426				475 426	
Financial liabilities						
Straight bond	249 748				249 748	249 774
Derivative financial liabilities			2 399		2 399	
Put options to non-controlling interests				6 011	6 011	
Lease liabilities	169 183				169 183	
Other financial liabilities	81 710				81 710	
Trade and other liabilities	450 111			230 376	680 487	

The changes in the carrying amounts associated with Level 3 financial instruments for the six months ended 30 June 2026 and 30 June 2025 are summarized as follows:

(in CHF 1000)	Financial assets	Financial liabilities
As at 1 January 2026	66 330	236 388
Additions	27 214	0
Settlements		(12 322)
Remeasurement recognized in profit or loss		10 766
Remeasurement recognized in OCI	1 502	0
Remeasurement recognized in equity		(8)
As at 30 June 2026	95 047	234 824

In H1 2026, additions to Level 3 financial assets primarily relate to a CHF 18.4 million investment in a China-based medical device supplier and a CHF 5.5 million investment in convertible bonds issued to Impress. The remeasurement of Level 3 financial liabilities recognized in profit or loss mainly reflects a fair value adjustment to the contingent consideration related to the AlliedStar acquisition. Settlements of Level 3 financial liabilities mainly include contingent consideration payments associated with the business combinations of the Baltic and Polish Distributors.

(in CHF 1000)	Financial assets	Financial liabilities
As at 1 January 2025	31 177	237 301
Additions	25 649	0
Remeasurement recognized in profit or loss	0	(16 123)
Settlements	0	(10 824)
Remeasurement recognized in OCI	(1 635)	(3)
Remeasurement recognized in equity	0	(253)
As at 30 June 2025	55 192	210 098

In H1 2025, additions to Level 3 financial assets primarily relate to a CHF 9.4 million investment in convertible bonds issued to Impress and a CHF 15.9 million equity investment in a Chinese entity active in the orthodontics market. The remeasurement of Level 3 financial liabilities recognized in profit or loss mainly reflects a fair value adjustment to the contingent consideration related to the AlliedStar acquisition. Settlements of Level 3 financial liabilities include contingent consideration payments associated with the business combinations of the Baltic and Polish Distributors.

During the six-month periods ended 30 June 2026 and 30 June 2025, there were no transfers between Level 1 and Level 2 fair value measurements, and no transfers into or out of Level 3 of the fair value hierarchy.

The significant unobservable inputs used in the valuation of material Level 3 financial instruments, together with a quantitative sensitivity analysis as of 30 June 2026, are presented below:

Instrument	Valuation technique	Significant unobservable input	Sensitivity of the input to fair value
Contingent Consideration AlliedStar	Present value of the estimated redemption value	Units sold	1 000 basis-point increase (decrease) in units sold would result in an increase (decrease) in fair value of CHF 9.6 million, resp. CHF -9.6 million.
		Share price	1 000 basis-point increase (decrease) in share price would result in an increase (decrease) in fair value of CHF 2.7 million, resp. CHF -2.7 million.
		Interest rate	100 basis-point increase (decrease) in the interest rate would result in a decrease (increase) in fair value of CHF -4.5 million, resp. CHF 4.7 million.
Contingent Consideration GalvoSurge	Present value of the estimated redemption value	Gross profit	1 000 basis-point increase (decrease) in gross profit would result in an increase (decrease) in fair value of CHF 1.3 million, resp. CHF -1.3 million.
		Interest rate	100 basis-point increase (decrease) in the interest rate would result in a decrease (increase) in fair value of CHF -0.7 million, resp. CHF 0.7 million.

The fair value of the contingent consideration for AlliedStar depends on technical and commercial milestone achievements, the share price development of Straumann Holding AG shares and the interest rate prevailing at the balance sheet date. For commercial milestone achievements, the expected redemption value is mainly dependent on the number of intraoral scanners sold, while for cash payments linked to the share price of Straumann Holding AG it is dependent on its share performance. The expected achievements have been assessed and result in a fair value of the contingent consideration of CHF 208.5 million at 30 June 2026 (31 December 2025: CHF 198.1 million).

The fair value of the contingent consideration for GalvoSurge mainly depends on commercial and technical milestones that are mainly sensitive to the gross profit of GalvoSurge products and the interest rate prevailing at the balance sheet date. The expected achievements have been assessed and result in a fair value of the contingent

consideration of CHF 13.4 million at 30 June 2026 (31 December 2025: CHF 13.4 million).

The Group did not disclose additional quantitative sensitivity analysis as of 30 June 2026 for the remaining Level 3 financial instruments, as their sensitivity is not considered material to the consolidated financial statements.

12 EVENTS AFTER THE BALANCE SHEET DATE

There were no significant events after the balance sheet date.

END OF DOCUMENT